91,921 Shares in Adaptive Biotechnologies Corporation $ADPT Purchased by Man Group plc

Man Group plc purchased a new position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 91,921 shares of the company’s stock, valued at approximately $1,972,000.

A number of other institutional investors also recently added to or reduced their stakes in ADPT. California State Teachers Retirement System grew its stake in shares of Adaptive Biotechnologies by 1.0% in the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock valued at $1,145,000 after purchasing an additional 933 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Adaptive Biotechnologies by 6.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 14,737 shares of the company’s stock worth $205,000 after buying an additional 941 shares during the period. Captrust Financial Advisors boosted its stake in Adaptive Biotechnologies by 7.6% in the 2nd quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock valued at $184,000 after buying an additional 1,119 shares in the last quarter. Assetmark Inc. boosted its stake in Adaptive Biotechnologies by 46.4% in the 1st quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock valued at $61,000 after buying an additional 1,401 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after acquiring an additional 1,565 shares during the period. 99.17% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies Stock Down 2.3%

NASDAQ ADPT opened at $24.34 on Wednesday. The stock has a market capitalization of $3.88 billion, a P/E ratio of -59.37 and a beta of 2.08. Adaptive Biotechnologies Corporation has a 52 week low of $12.00 and a 52 week high of $26.87. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. The stock has a fifty day moving average of $23.21 and a 200-day moving average of $17.79.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The firm had revenue of $71.55 million for the quarter, compared to analyst estimates of $65.44 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The company’s revenue was up 21.5% compared to the same quarter last year. During the same period last year, the company earned ($0.17) EPS. On average, equities research analysts forecast that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.

Insider Activity

In other news, CEO Chad M. Robins sold 278,676 shares of Adaptive Biotechnologies stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $24.48, for a total transaction of $6,821,988.48. Following the completion of the sale, the chief executive officer owned 2,180,518 shares in the company, valued at $53,379,080.64. The trade was a 11.33% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Harlan S. Robins sold 492,400 shares of Adaptive Biotechnologies stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $21.89, for a total transaction of $10,778,636.00. Following the sale, the insider owned 812,058 shares of the company’s stock, valued at approximately $17,775,949.62. This represents a 37.75% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 2,062,325 shares of company stock worth $46,659,069. Corporate insiders own 5.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. BTIG Research boosted their target price on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Guggenheim lifted their price target on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 30th. TD Cowen boosted their price target on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. JPMorgan Chase & Co. decreased their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Finally, Morgan Stanley raised their price objective on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Adaptive Biotechnologies has an average rating of “Moderate Buy” and an average price target of $24.42.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.